FDA approves a new drug to treat both relapsing-remitting multiple sclerosis and primary progressive MS.
Clinical trials show that a new drug called ocrelizumab can reduce attacks in people with RRMS, and can reduce new symptom development in patients with primary progressive multiple sclerosis.
Hydroxychloroquine shows promise for reducing some of the debilitating systems associated with primary progressive multiple sclerosis, a new study reports.
Researchers from Yale University have discovered tow cytokines that could help explain how some people develop PPMS. They report a simple genetic test could be used to identify those most at risk of developing progressive multiple sclerosis.
Clinical trials are showing positive results for the treatment of both relapsing multiple sclerosis and primary progressive MS.
According to researchers, a small preliminary study could show promise for a new treatment for those with primary progressive multiple sclerosis.
